Breaking barriers. Bridging gaps.
We are simplifying solid tumor cell therapy to advance a new path forward against cancer.
cTRLs are a highly sought after cell type
Circulating tumor-reactive lymphocytes (cTRLs), a subset of CD8+ T cells, have recently been identified as a rare and long sought-after cancer-fighting cell present in the blood.
The strength of cTRLs lies in their polyclonality, or the ability to recognize multiple tumor antigens across various cancers.
Preserving the inherent, highly desired features of cTRLs could pave a completely new path forward for the future of autologous solid tumor therapies.
cTRLs stem from a robust source of highly viable and functional antitumor immune cells. They have a unique molecular signature and memory phenotype characterized by reduced signs of dysfunction and exhaustion.
cTRL Therapeutics uses a proprietary magnetic-based technology called IsoQore, which gently isolates cTRLs in large quantities with unprecedented speed and purity in a manner that is built to scale.
Our technology has the ability to recover >95% of target cells, capturing the breadth of the tumor-reactive TCR repertoire. In contrast to other processes, which can damage cells during the isolation process, cTRL viability is preserved such that cells remain fully equipped to target the cancers they have been naturally programmed to destroy.
Our enabling technology platform: IsoQore™
With our proprietary platform, high quality cTRLs can be developed through a streamlined approach where T cells are accessed via peripheral blood.
Peripheral Blood
Harvesting cTRLs from the blood will allow broader applicability and many more patients to be treated compared to other approaches
Less Complex
Processing blood versus tumor will simplify tissue acquisition and manufacturing
Improved Quality
Highly viable, polyclonal
non-exhausted cells isolated in doses with defined composition may improve effectiveness
Advancing innovations and the next generation of cTRLs
cTRL is shaping the next generation of novel technologies and cell engineering approaches to drastically improve solid tumor cell therapies. Our lead asset, cTRL-001, is comprised of non-genetically modified cTRLs and compares favorably to other solid tumor cell therapy approaches. cTRL-001 shares key benefits of TILs and TCR-T, while avoiding some of their limitations.
Future development of cTRL-001 and next-generation product candidates will incorporate novel approaches to enhance efficacy, minimize AE’s and streamline manufacturing.